Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma

2016 ◽  
Vol 226 ◽  
pp. 193-204 ◽  
Author(s):  
Cong Zhang ◽  
Tong An ◽  
Dan Wang ◽  
Guoyun Wan ◽  
Mingming Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Anticancer Drugs ◽  
Glycolic Acid ◽  
Amino Ester ◽  
Ph Responsive

Disulfiram and disulfiram-loaded poly-[lactide-co-glycolic acid] nanoparticles modulate metastatic markers and proteasomal activity in hepatocarcinoma Hep3b cell line

2017 ◽  
Vol 9 (3-4) ◽  
Author(s):  
Muddasarul Hoda ◽  
Bindu Madhuri Cavuturu ◽  
Saleem Iqbal ◽  
Garima Shakya ◽  
Rukkumani Rajagopalan
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Line ◽  
Anticancer Drugs ◽  
High Mortality ◽  
Glycolic Acid ◽  
Mortality Rates ◽  
Hep3b Cell ◽  
Proteasomal Activity

AbstractHepatocellular carcinoma (HCC) results in significantly high mortality rates due to its subtle metastatic expressions. Exorbitant costs of anticancer drugs have lead to the concept of repositioning standard drugs for their anticancer potential. One such antialcoholic drug, disulfiram (DSF), has been reported to show significant cytotoxicity (IC

scholarly journals Self-Assembling pH-Responsive Nanoparticle Platform Based on Pectin–Doxorubicin Conjugates for Codelivery of Anticancer Drugs

ACS Omega ◽  
2021 ◽  
Author(s):  
Yinghua Tao ◽  
Dan Zheng ◽  
Jingyang Zhao ◽  
Kefeng Liu ◽  
Jing Liu ◽  
...  
Keyword(s):  
Anticancer Drugs ◽  
Ph Responsive ◽  
Self Assembling

Role of the Fas/FasL pathway in combination therapy with interferon-α and fluorouracil against hepatocellular carcinoma in vitro

2007 ◽  
Vol 46 (1) ◽  
pp. 77-88 ◽  
Author(s):  
Masato Nakamura ◽  
Hiroaki Nagano ◽  
Masato Sakon ◽  
Tameyoshi Yamamoto ◽  
Hideo Ota ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Interferon Α

scholarly journals Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Liangliang Yan ◽  
Yanqiao Ren ◽  
Kun Qian ◽  
Xuefeng Kan ◽  
Hongsen Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Combination Therapy ◽  
Clinical Outcomes ◽  
Transarterial Chemoembolization ◽  
Response Rate ◽  
Multivariable Analysis ◽  
Complication Rates ◽  
Tace Treatment

Abstract Background Transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) are effective treatment methods for unresectable hepatocellular carcinoma (HCC). However, there is still a lack of clinical research on whether early sequential RFA, compared with late combination therapy, can improve the long-term efficacy of initial TACE treatment. Methods This retrospective study investigated a cohort of patients who underwent combination therapy using TACE and RFA (TACE followed by RFA) from January 2010 to January 2020 at our medical centre. A total of 96 patients underwent TACE combined with early RFA (usually during the first hospitalization), which was called TACE + eRFA. Thirty-four patients received 1–2 palliative TACE treatments first and then underwent TACE treatment combined with late RFA (TACE + lRFA). All patients continued to receive palliative TACE treatments after intrahepatic lesion progression until reaching intolerance. The overall survival (OS) rate, time to tumour progression (TTP), tumour response rate and major complication rates were compared between the two groups. Results There were significant differences in the median OS (46 months vs 33 months; P = 0.013), median TTP (28 months vs 14 months; P < 0.00), objective response rate (ORR) (89.6% vs 61.8%, P = 0.000) and disease control rate (DCR) (94.8% vs 73.5% P = 0.002) between the two groups. Multivariable analysis revealed that the Barcelona Clinic Liver Cancer stage was an independent risk factor for OS. Meanwhile, multivariable analysis revealed that TACE + eRFA was associated with an enhanced TTP. Conclusion Early sequential RFA treatment in patients with early-intermediate HCC can improve local tumour control and clinical outcomes while reducing the frequency of TACE treatment. In clinical practice, in HCC patients initially treated with TACE, it is recommended to combine RFA as soon as possible to obtain long-term survival.

Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma

2003 ◽  
Vol 3 (8) ◽  
pp. 1169-1176 ◽  
Author(s):  
G Rasi ◽  
P Pierimarchi ◽  
P Sinibaldi Vallebona ◽  
F Colella ◽  
E Garaci
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis

scholarly journals Camptothecin suppresses NRF2–ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs

2017 ◽  
Vol 117 (10) ◽  
pp. 1495-1506 ◽  
Author(s):  
Feng Chen ◽  
Huihui Wang ◽  
Jiayu Zhu ◽  
Rui Zhao ◽  
Peng Xue ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Anticancer Drugs ◽  
Carcinoma Cells ◽  
Hepatocellular Carcinoma Cells
Sign in / Sign up

Export Citation Format

Share Document